These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 29434452)

  • 21. TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
    Kandioler D; Mittlböck M; Kappel S; Puhalla H; Herbst F; Langner C; Wolf B; Tschmelitsch J; Schippinger W; Steger G; Hofbauer F; Samonigg H; Gnant M; Teleky B; Kührer I;
    EBioMedicine; 2015 Aug; 2(8):825-30. PubMed ID: 26425688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
    Mei ZB; Duan CY; Li CB; Cui L; Ogino S
    Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival prediction model for non-small cell lung cancer based on somatic mutations.
    Zhang W; Lin X; Li X; Wang M; Sun W; Han X; Sun D
    J Gene Med; 2020 Sep; 22(9):e3206. PubMed ID: 32367667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
    Wang Q; Shi YL; Zhou K; Wang LL; Yan ZX; Liu YL; Xu LL; Zhao SW; Chu HL; Shi TT; Ma QH; Bi J
    Cell Death Dis; 2018 Jul; 9(7):739. PubMed ID: 29970892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
    Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
    Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
    Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
    Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
    Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance.
    Heczko L; Liška V; Vyčítal O; Fiala O; Šůsová S; Hlaváč V; Souček P
    Hum Genomics; 2024 Jul; 18(1):83. PubMed ID: 39030589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
    Hamaya Y; Guarinos C; Tseng-Rogenski SS; Iwaizumi M; Das R; Jover R; Castells A; Llor X; Andreu M; Carethers JM
    PLoS One; 2015; 10(5):e0127591. PubMed ID: 25996601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 mutations in advanced colorectal cancer: the dark side of the moon.
    Pietrantonio F; Biondani P; Perrone F; Di Bartolomeo M; Pacifici M; Milione M; Melotti F; Maggi C; Montemurro G; Bossi I; Mariani L; de Braud F
    Oncology; 2014; 86(5-6):289-94. PubMed ID: 24924261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.